Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Authors :: Zoe K, McQuilten
Ljoudmila, Busija
John F, Seymour
Simon, Stanworth
Erica M, Wood
Melita, Kenealy
Robert, Weinkove
Source :: Leukemia & Lymphoma. 63:676-683
Publication Year :: 2021
Publisher :: Informa UK Limited, 2021.
Abstract: Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a

Subjects :: Antimetabolites, Antineoplastic
Hemoglobins
Leukemia, Myeloid, Acute
Cancer Research
Dyspnea
Oncology
Myelodysplastic Syndromes
Azacitidine
Quality of Life
Humans
Hematology
Fatigue
Aged

Tools